GH Research ( (GHRS) ) has issued an announcement.
GH Research PLC reported its full year 2024 financial results and provided business updates on February 27, 2025. The company announced significant progress in its Phase 2b trial for GH001 in treatment-resistant depression, achieving a primary endpoint with a notable reduction in depression scores. Additionally, the company is addressing an FDA clinical hold on its GH001 IND application by completing requested studies and preparing a response. Financially, GH Research ended 2024 with $182.6 million in cash and equivalents, and raised $139.8 million from a public offering in February 2025.
More about GH Research
GH Research PLC is a clinical-stage biopharmaceutical company focused on transforming the treatment of psychiatric and neurological disorders. The company’s primary focus is on developing novel mebufotenin therapies for treatment-resistant depression (TRD).
YTD Price Performance: 38.69%
Average Trading Volume: 439,447
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $680.4M
For detailed information about GHRS stock, go to TipRanks’ Stock Analysis page.